Collectively, these findings highlight vinburnine as a promising candidate for melanoma treatment and suggest that targeting the IL-24/IL-20R2 axis may offer broader therapeutic benefits across multiple cancer types, particularly in combination with immune checkpoint inhibitors. The gene discussed is IL20RB; the disease is melanoma.